Matches in SemOpenAlex for { <https://semopenalex.org/work/W2157357845> ?p ?o ?g. }
- W2157357845 endingPage "22" @default.
- W2157357845 startingPage "1" @default.
- W2157357845 abstract "Alzheimer's disease (AD) is a slowly progressing non-linear dynamic brain disease in which pathophysiological abnormalities, detectable in vivo by biological markers, precede overt clinical symptoms by many years to decades. Use of these biomarkers for the detection of early and preclinical AD has become of central importance following publication of two international expert working group's revised criteria for the diagnosis of AD dementia, mild cognitive impairment (MCI) due to AD, prodromal AD and preclinical AD. As a consequence of matured research evidence six AD biomarkers are sufficiently validated and partly qualified to be incorporated into operationalized clinical diagnostic criteria and use in primary and secondary prevention trials. These biomarkers fall into two molecular categories: biomarkers of amyloid-beta (Aβ) deposition and plaque formation as well as of tau-protein related hyperphosphorylation and neurodegeneration. Three of the six gold-standard (core feasible) biomarkers are neuroimaging measures and three are cerebrospinal fluid (CSF) analytes. CSF Aβ1-42 (Aβ1-42), also expressed as Aβ1-42 : Aβ1-40 ratio, T-tau, and P-tau Thr181 & Thr231 proteins have proven diagnostic accuracy and risk enhancement in prodromal MCI and AD dementia. Conversely, having all three biomarkers in the normal range rules out AD. Intermediate conditions require further patient follow-up. Magnetic resonance imaging (MRI) at increasing field strength and resolution allows detecting the evolution of distinct types of structural and functional abnormality pattern throughout early to late AD stages. Anatomical or volumetric MRI is the most widely used technique and provides local and global measures of atrophy. The revised diagnostic criteria for prodromal AD and mild cognitive impairment due to AD include hippocampal atrophy (as the fourth validated biomarker), which is considered an indicator of regional neuronal injury. Advanced image analysis techniques generate automatic and reproducible measures both in regions of interest, such as the hippocampus and in an exploratory fashion, observer and hypothesis-indedendent, throughout the entire brain. Evolving modalities such as diffusion-tensor imaging (DTI) and advanced tractography as well as resting-state functional MRI provide useful additionally useful measures indicating the degree of fiber tract and neural network disintegration (structural, effective and functional connectivity) that may substantially contribute to early detection and the mapping of progression. These modalities require further standardization and validation. The use of molecular in vivo amyloid imaging agents (the fifth validated biomarker), such as the Pittsburgh Compound-B and markers of neurodegeneration, such as fluoro-2-deoxy-D-glucose (FDG) (as the sixth validated biomarker) support the detection of early AD pathological processes and associated neurodegeneration. How to use, interpret, and disclose biomarker results drives the need for optimized standardization. Multimodal AD biomarkers do not evolve in an identical manner but rather in a sequential but temporally overlapping fashion. Models of the temporal evolution of AD biomarkers can take the form of plots of biomarker severity (degree of abnormality) versus time. AD biomarkers can be combined to increase accuracy or risk. A list of genetic risk factors is increasingly included in secondary prevention trials to stratify and select individuals at genetic risk of AD. Although most of these biomarker candidates are not yet qualified and approved by regulatory authorities for their intended use in drug trials, they are nonetheless applied in ongoing clinical studies for the following functions: (i) inclusion/exclusion criteria, (ii) patient stratification, (iii) evaluation of treatment effect, (iv) drug target engagement, and (v) safety. Moreover, novel promising hypothesis-driven, as well as exploratory biochemical, genetic, electrophysiological, and neuroimaging markers for use in clinical trials are being developed. The current state-of-the-art and future perspectives on both biological and neuroimaging derived biomarker discovery and development as well as the intended application in prevention trials is outlined in the present publication." @default.
- W2157357845 created "2016-06-24" @default.
- W2157357845 creator A5001795846 @default.
- W2157357845 creator A5002348728 @default.
- W2157357845 creator A5005778444 @default.
- W2157357845 creator A5021920622 @default.
- W2157357845 creator A5024787899 @default.
- W2157357845 creator A5031114437 @default.
- W2157357845 creator A5031617464 @default.
- W2157357845 creator A5033321689 @default.
- W2157357845 creator A5033714718 @default.
- W2157357845 creator A5034225628 @default.
- W2157357845 creator A5034473058 @default.
- W2157357845 creator A5035699131 @default.
- W2157357845 creator A5036841670 @default.
- W2157357845 creator A5037109052 @default.
- W2157357845 creator A5049484291 @default.
- W2157357845 creator A5051461733 @default.
- W2157357845 creator A5051959460 @default.
- W2157357845 creator A5053401725 @default.
- W2157357845 creator A5059020389 @default.
- W2157357845 creator A5059630674 @default.
- W2157357845 creator A5060487287 @default.
- W2157357845 creator A5065258380 @default.
- W2157357845 creator A5068394264 @default.
- W2157357845 creator A5069514442 @default.
- W2157357845 creator A5070256596 @default.
- W2157357845 creator A5075804608 @default.
- W2157357845 creator A5077078681 @default.
- W2157357845 creator A5078876988 @default.
- W2157357845 creator A5079134234 @default.
- W2157357845 creator A5087905843 @default.
- W2157357845 creator A5088896716 @default.
- W2157357845 date "2014-01-01" @default.
- W2157357845 modified "2023-10-09" @default.
- W2157357845 title "THE ROAD AHEAD TO CURE ALZHEIMER'S DISEASE: DEVELOPMENT OF BIOLOGICAL MARKERS AND NEUROIMAGING METHODS FOR PREVENTION TRIALS ACROSS ALL STAGES AND TARGET POPULATIONS" @default.
- W2157357845 cites W1507990444 @default.
- W2157357845 cites W1514687927 @default.
- W2157357845 cites W1523984875 @default.
- W2157357845 cites W1530928952 @default.
- W2157357845 cites W1546597559 @default.
- W2157357845 cites W1555076800 @default.
- W2157357845 cites W1559001474 @default.
- W2157357845 cites W1565795595 @default.
- W2157357845 cites W1578451937 @default.
- W2157357845 cites W1585083630 @default.
- W2157357845 cites W1594504409 @default.
- W2157357845 cites W1628671467 @default.
- W2157357845 cites W1700602755 @default.
- W2157357845 cites W1710470277 @default.
- W2157357845 cites W1730714147 @default.
- W2157357845 cites W1751963152 @default.
- W2157357845 cites W176409249 @default.
- W2157357845 cites W1783658541 @default.
- W2157357845 cites W1937302929 @default.
- W2157357845 cites W1944121002 @default.
- W2157357845 cites W1944724818 @default.
- W2157357845 cites W19615207 @default.
- W2157357845 cites W1964464904 @default.
- W2157357845 cites W1966144812 @default.
- W2157357845 cites W1966378897 @default.
- W2157357845 cites W1967005522 @default.
- W2157357845 cites W1967097461 @default.
- W2157357845 cites W1967130818 @default.
- W2157357845 cites W1967229678 @default.
- W2157357845 cites W1967737804 @default.
- W2157357845 cites W1968231693 @default.
- W2157357845 cites W1968790254 @default.
- W2157357845 cites W1969215488 @default.
- W2157357845 cites W1969787718 @default.
- W2157357845 cites W1970988922 @default.
- W2157357845 cites W1971434214 @default.
- W2157357845 cites W1972025839 @default.
- W2157357845 cites W1974528285 @default.
- W2157357845 cites W1977610079 @default.
- W2157357845 cites W1977654293 @default.
- W2157357845 cites W1977714477 @default.
- W2157357845 cites W1977946208 @default.
- W2157357845 cites W1978482448 @default.
- W2157357845 cites W1982182604 @default.
- W2157357845 cites W1982974584 @default.
- W2157357845 cites W1983349802 @default.
- W2157357845 cites W1985058290 @default.
- W2157357845 cites W1986752522 @default.
- W2157357845 cites W1987011701 @default.
- W2157357845 cites W1987157607 @default.
- W2157357845 cites W1988122824 @default.
- W2157357845 cites W1988840297 @default.
- W2157357845 cites W1990275483 @default.
- W2157357845 cites W1991282216 @default.
- W2157357845 cites W1991361327 @default.
- W2157357845 cites W1993571512 @default.
- W2157357845 cites W1994839012 @default.
- W2157357845 cites W1997166338 @default.
- W2157357845 cites W1997301424 @default.
- W2157357845 cites W2000178490 @default.
- W2157357845 cites W2000561520 @default.
- W2157357845 cites W2000566928 @default.